Aquaporin-4-autoimmunity in patients with systemic lupus erythematosus: A predominantly population-based study

Abstract

Background:

Serum immunoglobulin G targeting the astrocyte water channel aquaporin-4 (AQP4) in the central nervous system (CNS) is a biomarker for neuromyelitis optica spectrum disease (NMOSD). Co-existence of NMOSD with systemic lupus erythematosus (SLE) putatively suggests susceptibility to antibody-mediated autoimmune disease.

Objective:

To estimate the prevalence of NMOSD in SLE and investigate the immunogenetic background for an association of NMOSD and SLE.

Methods:

The study included a predominantly population-based cohort with clinical and serological investigations of 208 patients with SLE, followed prospectively since 1995. All patients received immunosuppressive treatment. NMOSD was evaluated retrospectively based on the 2015 International Panel for NMOSD Diagnosis (IPND) criteria. Polymorphisms in programmed cell death protein 1 (PDCD-1) PD-1.3 G/A were genotyped. AGP4-IgG and other autoantibodies, including myelin oligodendrocyte glycoprotein (MOG), was determined blinded to clinical diagnosis.

Results:

Of 208 patients with SLE, 45(22%) had neuropsychiatric (NP) SLE, and CNS involvement predominated in 30 of 45 (67%) patients. Serum AQP4-IgG was detected in 2 of 30 (6.7%) neuropsychiatric SLE (NPSLE) patients both of whom had myelitis and antiphospholipid syndrome; one patient also had myasthenia gravis. None had MOG-IgG. PD-1.3A allele was not associated with SLE nor with NPSLE.

Conclusion:

AQP4-IgG autoimmune syndrome may rarely co-exist with SLE, and such patients have other NMOSD-typical syndromes such as myelitis.

Keywords

Epidemiology neuromyelitis optica spectrum disease systemic lupus erythematosus aquaporin-IgG myelin oligodendrocyte glycoprotein-IgG programmed death 1

Get full access to this article

View all access options for this article.

References

Wingerchuk

Lennon

Lucchinetti

et al . The spectrum of neuromyelitis optica. Lancet Neurol 2007; 6: 805–815.

Pandit

Asgari

Apiwattanakul

et al . Demographic and clinical features of neuromyelitis optica: A review. Mult Scler 2015; 21: 845–853.

Lennon

Wingerchuk

Kryzer

et al . A serum autoantibody marker of neuromyelitis optica: Distinction from multiple sclerosis. Lancet 2004; 364: 2106–2112.

Lennon

Kryzer

Pittock

et al . IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J Exp Med 2005; 202: 473–477.

Lucchinetti

Mandler

McGavern

et al . A role for humoral mechanisms in the pathogenesis of Devic’s neuromyelitis optica. Brain 2002; 125: 1450–1461.

Jarius

Ruprecht

Kleiter

et al . MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 2: Epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome. J Neuroinflammation 2016; 13: 280.

Pittock

Lennon

de Seze

et al . Neuromyelitis optica and non organ-specific autoimmunity. Arch Neurol 2008; 65: 78–83.

Wingerchuk

Weinshenker

BG.

The emerging relationship between neuromyelitis optica and systemic rheumatologic autoimmune disease. Mult Scler 2012; 18: 5–10.

Jarius

Jacobi

de Seze

et al . Frequency and syndrome specificity of antibodies to aquaporin-4 in neurological patients with rheumatic disorders. Mult Scler 2011; 17: 1067–1073.

10.

Hanly

JG.

Diagnosis and management of neuropsychiatric SLE. Nat Rev Rheumatol 2014; 10: 338–347.

11.

Trysberg

Nylen

Rosengren

et al . Neuronal and astrocytic damage in systemic lupus erythematosus patients with central nervous system involvement. Arthritis Rheum 2003; 48: 2881–2887.

12.

Asgari

Nielsen

Stenager

et al . HLA, PTPN22 and PD-1 associations as markers of autoimmunity in neuromyelitis optica. Mult Scler 2012; 18: 23–30.

13.

Voss

Green

Junker

Systemic lupus erythematosus in Denmark: Clinical and epidemiological characterization of a county-based cohort. Scand J Rheumatol 1998; 27: 98–105.

14.

Fries

Holman

HR.

Systemic lupus erythematosus: A clinical analysis, Major problems in internal medicine. JAMA 1975; 112: 1805.

15.

Hochberg

MC.

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

16.

Laustrup

Voss

Green

et al . Occurrence of systemic lupus erythematosus in a Danish community: An 8-year prospective study. Scand J Rheumatol 2009; 38: 128–132.

17.

Wingerchuk

Banwell

Bennett

et al . International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 2015; 85: 177–189.

18.

Jarius

Metz

Konig

et al . Screening for MOG-IgG and 27 other anti-glial and anti-neuronal autoantibodies in ‘pattern II multiple sclerosis’ and brain biopsy findings in a MOG-IgG-positive case. Mult Scler 2016; 22: 1541–1549.

19.

Waters

Woodhall

O’Connor

et al . MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2015; 2: e89.

20.

Jarius

Ruprecht

Kleiter

et al . MOG-IgG in NMO and related disorders: A multicenter study of 50 patients. Part 1: Frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin. J Neuroinflammation 2016; 13: 279.

21.

Loizou

McCrea

Rudge

et al . Measurement of anti-cardiolipin antibodies by an enzyme-linked immunosorbent assay (ELISA): Standardization and quantitation of results. Clin Exp Immunol 1985; 62: 738–745.

22.

Laustrup

Voss

Green

et al . SLE disease patterns in a Danish population-based lupus cohort: An 8-year prospective study. Lupus 2010; 19: 239–246.

23.

Schantz

Oestergaard

Junker

Shrinking spinal cord following transverse myelopathy in a patient with systemic lupus erythematosus and the phospholipid antibody syndrome. J Rheumatol 1998; 25: 1425–1428.

24.

Wandinger

Stangel

Witte

et al . Autoantibodies against aquaporin-4 in patients with neuropsychiatric systemic lupus erythematosus and primary Sjogren’s syndrome. Arthritis Rheum 2010; 62: 1198–1200.

25.

Jarius

Frederikson

Waters

et al . Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 2010; 298: 158–162.

26.

Zavada

Nytrova

Wandinger

et al . Seroprevalence and specificity of NMO-IgG (anti-aquaporin 4 antibodies) in patients with neuropsychiatric systemic lupus erythematosus. Rheumatol Int 2013; 33: 259–263.

27.

Squatrito

Colagrande

Emmi

Devic’s syndrome and primary APS: A new immunological overlap. Lupus 2010; 19: 1337–1339.

28.

Guerra

Pittock

Moder

et al . Neuromyelitis optica spectrum initially diagnosed as antiphospholipid antibody myelitis. J Neurol Sci 2016; 361: 204–205.

29.

Leite

Coutinho

Lana-Peixoto

et al . Myasthenia gravis and neuromyelitis optica spectrum disorder: A multicenter study of 16 patients. Neurology 2012; 78: 1601–1607.

30.

Asgari

Lillevang

Skejoe

et al . A population-based study of neuromyelitis optica in Caucasians. Neurology 2011; 76:1589–1595.

31.

Ramanujam

Davidson

Targeting of the immune system in systemic lupus erythematosus. Expert Rev Mol Med 2008; 10: e2.

32.

Bennett

O’Connor

Bar-Or

et al . B lymphocytes in neuromyelitis optica. Neurol Neuroimmunol Neuroinflamm 2015; 2: e104.

33.

Nishimura

Nose

Hiai

et al . Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999; 11: 141–151.

34.

Nielsen

Laustrup

Voss

et al . A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients. Lupus 2004; 13: 510–516.

35.

Mader

Gredler

Schanda

et al . Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. J Neuroinflammation 2011; 8: 184.